Pain Increases After Shoulder Injection

C

Campbell Clinic

Status and phase

Completed
Phase 4

Conditions

Shoulder Pain

Treatments

Drug: Triamcinolone Acetonide (TA)
Drug: Methylprednisolone (MPA)

Study type

Interventional

Funder types

Other

Identifiers

NCT05438277
IRB 7001-XP

Details and patient eligibility

About

Compare FLARE reactions (increase in VAS by two or more points) in the first 48 hours following a shoulder injection.

Full description

Corticosteroid injections are used to reduce pain and inflammation for various shoulder pathologies. Corticosteroid flare reaction is a well-described phenomenon that, despite being self-limited, causes significant pain and dysfunction. A flare reaction is defined for the purposes the study to be an increase of two or more points on a visual analog scale reported by the subject. Currently, there is a paucity of literature to drive the decision-making process between different corticosteroid medications. This study will compare the incidences of steroid flare reaction and three-month efficacy following methylprednisolone acetate (MPA) and triamcinolone acetonide (TA) corticosteroid injections into the glenohumeral joint or subacromial space. Physicians administering a steroid injection in the shoulder will utilize MPA until 200 subjects have agreed to participate in this treatment arm. Enrollment will then be offered to 200 subjects utilizing TA for the shoulder injection. Subjects receive treatment for their shoulder pain regardless of willingness to participate in the follow up reported pain scores. There are no costs to subjects for study participation.

Enrollment

421 patients

Sex

All

Ages

18 to 99 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Subacromial or glenohumeral shoulder pain to be treated with steroid injection
  • Fluent in written and oral English
  • Willing and able to provide written consent
  • Willing to complete follow up pain scores (visual analog score)

Exclusion criteria

  • Unable to provide written consent
  • Chronic pain syndrome
  • Unwilling to complete follow up pain scores (visual analog score)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

421 participants in 2 patient groups

methylprednisolone acetate (MPA)
Experimental group
Description:
subacromial or glenohumeral shoulder injection
Treatment:
Drug: Methylprednisolone (MPA)
triamcinolone acetonide (TA)
Active Comparator group
Description:
subacromial or glenohumeral shoulder injection
Treatment:
Drug: Triamcinolone Acetonide (TA)

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems